We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Astrazeneca (AZN - Free Report) to post quarterly earnings of $2.18 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $15.78 billion, up 6% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Astrazeneca metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Alliance Revenue- Total' will likely reach $875.42 million. The estimate suggests a change of +22.6% year over year.
The average prediction of analysts places 'Collaboration Revenue- Total' at $173.65 million. The estimate indicates a change of -78.7% from the prior-year quarter.
The consensus estimate for 'BioPharmaceuticals- V&I- Synagis- Established RoW' stands at $38.47 million. The estimate points to a change of +28.2% from the year-ago quarter.
Analysts' assessment points toward 'BioPharmaceuticals- R&I- Symbicort- World' reaching $695.87 million. The estimate indicates a change of +1.7% from the prior-year quarter.
The consensus among analysts is that 'BioPharmaceuticals- V&I- U.S.' will reach $117.31 million. The estimate indicates a year-over-year change of +46.6%.
It is projected by analysts that the 'BioPharmaceuticals- R&I- Symbicort- U.S.' will reach $309.80 million. The estimate indicates a change of +3.6% from the prior-year quarter.
According to the collective judgment of analysts, 'BioPharmaceuticals- CVRM- Crestor- U.S.' should come in at $10.74 million. The estimate points to a change of -17.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Oncology- Tagrisso- U.S.' of $859.75 million. The estimate indicates a year-over-year change of +12.1%.
Analysts forecast 'BioPharmaceuticals- R&I- Fasenra- U.S.' to reach $339.58 million. The estimate points to a change of +13.6% from the year-ago quarter.
Analysts predict that the 'BioPharmaceuticals- CVRM- Brilinta- U.S.' will reach $64.66 million. The estimate indicates a year-over-year change of -68.9%.
Analysts expect 'Oncology- Lynparza- U.S.' to come in at $394.55 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Oncology- Imfinzi- U.S.' should arrive at $964.07 million. The estimate indicates a year-over-year change of +33.7%.
Shares of Astrazeneca have experienced a change of -1.5% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), AZN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect Astrazeneca (AZN - Free Report) to post quarterly earnings of $2.18 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $15.78 billion, up 6% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Astrazeneca metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Alliance Revenue- Total' will likely reach $875.42 million. The estimate suggests a change of +22.6% year over year.
The average prediction of analysts places 'Collaboration Revenue- Total' at $173.65 million. The estimate indicates a change of -78.7% from the prior-year quarter.
The consensus estimate for 'BioPharmaceuticals- V&I- Synagis- Established RoW' stands at $38.47 million. The estimate points to a change of +28.2% from the year-ago quarter.
Analysts' assessment points toward 'BioPharmaceuticals- R&I- Symbicort- World' reaching $695.87 million. The estimate indicates a change of +1.7% from the prior-year quarter.
The consensus among analysts is that 'BioPharmaceuticals- V&I- U.S.' will reach $117.31 million. The estimate indicates a year-over-year change of +46.6%.
It is projected by analysts that the 'BioPharmaceuticals- R&I- Symbicort- U.S.' will reach $309.80 million. The estimate indicates a change of +3.6% from the prior-year quarter.
According to the collective judgment of analysts, 'BioPharmaceuticals- CVRM- Crestor- U.S.' should come in at $10.74 million. The estimate points to a change of -17.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Oncology- Tagrisso- U.S.' of $859.75 million. The estimate indicates a year-over-year change of +12.1%.
Analysts forecast 'BioPharmaceuticals- R&I- Fasenra- U.S.' to reach $339.58 million. The estimate points to a change of +13.6% from the year-ago quarter.
Analysts predict that the 'BioPharmaceuticals- CVRM- Brilinta- U.S.' will reach $64.66 million. The estimate indicates a year-over-year change of -68.9%.
Analysts expect 'Oncology- Lynparza- U.S.' to come in at $394.55 million. The estimate indicates a change of +4.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Oncology- Imfinzi- U.S.' should arrive at $964.07 million. The estimate indicates a year-over-year change of +33.7%.
View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have experienced a change of -1.5% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), AZN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .